Blog
RSS FeedPosted by Michael Wonder on 14 Oct 2021
Novartis and the pan-Canadian Pharmaceutical Alliance complete negotiations for Zolgensma for the treatment of paediatric patients with spinal muscular atrophy
13 October 2021 - Novartis Pharmaceuticals Canada today announced that it has completed negotiations with the pan-Canadian Pharmaceutical Alliance for a ...
Posted by Michael Wonder on 28 Sep 2021
Onpattro (patisiran) now reimbursed in Canada for the treatment of hereditary transthyretin mediated amyloidosis
28 September 2021 - Onpattro is the only treatment that has demonstrated improvement in both polyneuropathy and quality of life ...
Posted by Michael Wonder on 26 Sep 2021
Manitoba family calling for province to cover life-changing drug
26 September 2021 - A new drug called Trikafta could be a life-changing treatment option for people living with cystic ...
Posted by Michael Wonder on 25 Sep 2021
Ontario providing access to life changing treatment for cystic fibrosis patients
24 September 2021 - Ontario is now providing coverage for Trikafta, the latest and most effective treatment option for cystic fibrosis ...
Posted by Michael Wonder on 20 Sep 2021
Vertex announces letter of intent with pan-Canadian Pharmaceutical Alliance for public reimbursement of CFTR modulators Extended to Include Trikafta (elexacaftor/tezacaftor/ivacaftor and ivacaftor)
17 September 2021 - Vertex Pharmaceuticals today announced that it has signed a letter of intent with the pan-Canadian Pharmaceutical ...
Posted by Michael Wonder on 21 Aug 2021
Cystic fibrosis patients, advocates urge Ontario government to provide ‘miracle drug’ funding
20 August 2021 - An Ontario teen living with Cystic Fibrosis and her mother are hoping to shine a light ...
Posted by Michael Wonder on 14 Aug 2021
Halifax man devastated after insurer reverses decision to cover $25,000 cystic fibrosis drug
13 August 2021 - Stefan Strecko says he's pleaded with Canada Life to cover cost of 'miracle' drug. ...
Posted by Michael Wonder on 31 Jul 2021
Frustrated cystic fibrosis patient speaks out after drug coverage denial
30 July 2021 - Twenty eight year old cystic fibrosis patient Stefan Strecko says he went from jubilation to devastation ...
Posted by Michael Wonder on 15 Jul 2021
Cystic fibrosis patients upset over recommended restrictive criteria for life saving drug
15 July 2021 - 'By narrowly defining accessibility and continuation criteria CADTH’s recommendation overlooks many of Trikafta’s significant benefits,' says chief ...
Posted by Michael Wonder on 13 Jul 2021
'A price on your life': Toronto cystic fibrosis patients slam review process while waiting for access to life-saving treatment
13 July 2021 - While Health Canada approved Trikafta for patient use on June 18, 2021, it is still not ...
Posted by Michael Wonder on 23 Jun 2021
Rare disease patient advocates continue battle for affordable drugs
23 June 2021 - Beth Vanstone, mother of local Cystic Fibrosis Warrior Madi Vanstone and director of the CF Get ...
Posted by Michael Wonder on 18 Jun 2021
Let's have permanently quicker drug approvals
16 June 2021 - New drugs and vaccines likely to increase life expectancy, quality of life and save money, so we ...
Posted by Michael Wonder on 03 Jun 2021
Quebec extends public reimbursement of Dupixent (dupilumab) for the treatment of moderate to severe atopic dermatitis to include adolescents
1 June 2021 - Public reimbursement under the Régie de l'assurance maladie du Québec will now apply for Canadians aged ...
Posted by Michael Wonder on 31 May 2021
Campaign launched for life-sustaining treatment access across Canada
31 May 2021 - Alpha-1 Canada publicly launched Access for Alphas today, a campaign aimed at raising the awareness of alfa-1 ...
Posted by Michael Wonder on 25 May 2021
Dupixent (dupilumab) now publicly reimbursed in Ontario and New Brunswick for the treatment of moderate to severe atopic dermatitis
25 May 2021 - Dupixent is the only biologic medicine approved by Health Canada to treat moderate to severe atopic dermatitis. ...